Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Algae, particularly certain species such as Spirulina and Chlorella, have been investigated for their potential role in supporting or treating non-alcoholic fatty liver disease (NAFLD). The scientific justification stems from several animal and limited human studies suggesting that algae-derived compounds may help reduce hepatic fat accumulation, inflammation, and oxidative stress—core factors in the pathogenesis of fatty liver disease. Key components in algae, such as phycocyanin (from Spirulina), antioxidants, and polyunsaturated fatty acids, are believed to exert hepatoprotective effects.

For example, a 2013 animal study published in Lipids in Health and Disease showed that Spirulina supplementation reduced liver fat and improved lipid profiles in rats fed a high-fat diet. Small clinical trials have also indicated that Spirulina and Chlorella supplementation may reduce liver enzyme levels (ALT, AST) in patients with NAFLD, though the sample sizes are often small and methodologies vary.

Despite these promising findings, the overall quality of evidence remains moderate to low. Most studies are preclinical or involve small human cohorts, and the exact mechanisms are not fully elucidated. Larger, well-designed clinical trials are needed before algae can be broadly recommended for fatty liver disease. Therefore, the evidence rating is 2: preliminary scientific support exists, but it is not yet robust or definitive.

More about algae
More about Fatty Liver Disease

Other ingredients used for Fatty Liver Disease

Other health conditions supported by algae

Products containing algae

Douglas Laboratories THYROMEND™